← Leaderboards
Wendy S. Garrett
Dana-Farber Cancer Inst
$9,434,998
Attributed
$16,057,614
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2009–25$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,057,614 · 6
By mechanism
R01$14,968,925 · 4
K08$664,752 · 1
R21$423,937 · 1
Top collaborators
- Andrew T Chan10 shared
- Mark A Hull6 shared
- Curtis Huttenhower5 shared
- Jacques G Izard5 shared
- John M Leong5 shared
- Cammie Lesser5 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Susan Bullman$2,443,832
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelImmuneMicrobeBacteriaColorectal CancerMediatingTumorCellsProductionInsightGut MicrobiotaMicrobialMalignant NeoplasmsInflammationMicrobiotaInflammatoryBaseTissuesResponseMicrobial CommunityGut MicrobiomeMetabolicChronicTumor Microenvironment
Grant awards (39)
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology$757,626
R01 · FY2025 · CA · contact PI
Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer livermetastasis$710,138
R01 · FY2024 · CA · contact PI
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology$359,872
R01 · FY2024 · CA · contact PI
Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer$1
R01 · FY2024 · CA
Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer$599,135
R01 · FY2023 · CA
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology$378,813
R01 · FY2023 · CA · contact PI
Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer$605,801
R01 · FY2022 · CA
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology$378,813
R01 · FY2022 · CA · contact PI
Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer$626,197
R01 · FY2021 · CA
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology$346,690
R01 · FY2021 · CA · contact PI
Designer Probiotics for the treatment of intestinal infection and inflammation$733,448
R01 · FY2020 · DK
Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer$643,839
R01 · FY2020 · CA
Dietary sulfur, the gut microbiome, and colorectal cancer$544,699
R01 · FY2020 · CA
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology$346,690
R01 · FY2020 · CA · contact PI
Designer Probiotics for the treatment of intestinal infection and inflammation$735,149
R01 · FY2019 · DK
Dietary sulfur, the gut microbiome, and colorectal cancer$583,199
R01 · FY2019 · CA
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology$336,288
R01 · FY2019 · CA · contact PI
Designer Probiotics for the treatment of intestinal infection and inflammation$735,149
R01 · FY2018 · DK
Dietary sulfur, the gut microbiome, and colorectal cancer$556,619
R01 · FY2018 · CA
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology$346,690
R01 · FY2018 · CA · contact PI
Designer Probiotics for the treatment of intestinal infection and inflammation$744,110
R01 · FY2017 · DK
Dietary sulfur, the gut microbiome, and colorectal cancer$555,785
R01 · FY2017 · CA
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology$346,690
R01 · FY2017 · CA · contact PI
Designer Probiotics for the treatment of intestinal infection and inflammation$787,620
R01 · FY2016 · DK
Dietary sulfur, the gut microbiome, and colorectal cancer$596,028
R01 · FY2016 · CA
The gut microbiota and ethanol$191,781
R21 · FY2016 · AA · contact PI
Gut microbiota and inflammatory monocytes in colorectal cancer$335,113
R01 · FY2015 · CA · contact PI
The gut microbiota and ethanol$232,156
R21 · FY2015 · AA · contact PI
Gut microbiota and inflammatory monocytes in colorectal cancer$325,060
R01 · FY2014 · CA · contact PI
Gut microbiota and inflammatory monocytes in colorectal cancer$315,006
R01 · FY2013 · CA · contact PI
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis$125,199
K08 · FY2013 · AI · contact PI
Gut microbiota and inflammatory monocytes in colorectal cancer$335,113
R01 · FY2012 · CA · contact PI
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis$125,199
K08 · FY2012 · AI · contact PI
Gut microbiota and inflammatory monocytes in colorectal cancer$303,544
R01 · FY2011 · CA · contact PI
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis$125,199
K08 · FY2011 · AI · contact PI
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis$125,091
K08 · FY2010 · AI · contact PI
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis$33,924
K08 · FY2010 · AI · contact PI
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis$99,320
K08 · FY2009 · AI · contact PI
Disease Initation and the role of DCs in the TRUC Model of ulcerative colitis$30,820
K08 · FY2009 · AI · contact PI